Rationale
- Pairing an Oscillating Positive Expiratory Pressure (OPEP) device with a Breath Actuated Nebulizer (BAN) offers the opportunity to deliver bronchodilator therapy during inhalation with secretion clearance during exhalation thereby reducing combined treatment time.
- Aerosol deposition scintigraphy was undertaken to assess in vivo pulmonary deposition from an AEROECLIPSE* II BAN* (Breath Actuated Nebulizer) coupled to an Aerobika* OPEP device, compared to deposition from the nebulizer alone.
Conclusion
- The delivery of medication from the AEROECLIPSE* II BAN* to the lungs was not affected by the incorporation of the Aerobika* OPEP device. Aerosol deposition within the lung was unaltered by the addition of the OPEP device as evidenced by the near identical percentage of the dose being deposited in both the peripheral and central airways.
- BAN+OPEP therapy could offer the clinician the opportunity for combined treatment thereby reducing the time needed for the patient to take both nebulizer and OPEP treatments separately.